Allergic Endotypes and Phenotypes of Asthma.
Allergic Endotypes and Phenotypes of Asthma.
复制标题
DOI：
10.1016/j.jaip.2019.11.008
复制
发表时间：
2020-02
期刊：
影响因子：
--
通讯作者：
Phipatanakul W
中科院分区：
文献类型：
--
作者：
Akar-Ghibril N;Casale T;Custovic A;Phipatanakul W
过敏性哮喘被定义为与空气过敏原过敏相关的哮喘，导致哮喘症状和气道炎症。过敏性哮喘是最常见的哮喘表型。过敏性哮喘最常见于儿童期，通常伴有其他合并症，包括特应性皮炎和过敏性鼻炎。尽管疾病严重程度差异很大，但它通常是持续存在的。这是一个 TH2 驱动的过程。已确定用于区分过敏性哮喘患者的生物标志物，特别是血清 IgE 水平、指示对空气过敏原过敏的测试（例如特定 IgE 或皮肤点刺试验阳性）、血液和痰液嗜酸性粒细胞水平、呼出一氧化氮分数和骨膜素。过敏性哮喘的治疗包括环境控制措施、过敏原免疫疗法和糖皮质激素。针对 TH2 通路的生物制剂已被证明可有效治疗过敏性哮喘。
Allergic asthma is defined as asthma associated with sensitization to aeroallergens, which leads to asthma symptoms and airway inflammation. Allergic asthma is the most common asthma phenotype. The onset of allergic asthma is most often in childhood and is usually accompanied by other comorbidities including atopic dermatitis and allergic rhinitis. It is often persistent although there is a wide variation in disease severity. It is a TH2-driven process. Biomarkers have been identified to distinguish patients with allergic asthma, particularly serum IgE levels, tests to indicate sensitization to aeroallergens such as specific IgE or skin prick test positivity, blood and sputum eosinophil levels, fraction of exhaled nitric oxide, and periostin. Treatments for allergic asthma include environmental control measures, allergen immunotherapy, and glucocorticoids. Biologics, targeting the TH2 pathway, have been shown to be effective in the treatment of allergic asthma.
登录
查看更多内容
影响因子：
14.2
作者：
Busse, W;Corren, J;Gupta, N
通讯作者：
Gupta, N
DOI：
10.1016/j.jaip.2018.04.043
发表时间：
2019-01-01
影响因子：
9.4
作者：
Casale, Thomas B.;Luskin, Allan T.;Chipps, Bradley E.
通讯作者：
Chipps, Bradley E.
影响因子：
14.2
作者：
Arbes, Samuel J., Jr.;Gergen, Peter J.;Zeldin, Darryl C.
通讯作者：
Zeldin, Darryl C.
影响因子：
1.9
作者：
Bardelas, Jose;Figliomeni, Maria;Meng, Xiangyi
通讯作者：
Meng, Xiangyi
影响因子：
9.6
作者：
Bjermer, Leif;Lemiere, Catherine;Germinaro, Matthew
通讯作者：
Germinaro, Matthew